NCT07102446 Evaluation of an Opioid Stewardship Program in Non-Cancer Patients
| NCT ID | NCT07102446 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Korea University Guro Hospital |
| Condition | Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2025-06-27 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2025-06-27 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this prospective, non-randomized clinical trial is to evaluate the effectiveness of a pharmacist-led Opioid Stewardship Program (OSP) in outpatient adults with chronic non-cancer pain. This study compared OSP implementation with a historical control to determine whether it reduces the incidence of high-risk opioid prescribing and improves patients' awareness, knowledge, and attitudes about opioid use.
Eligibility Criteria
Inclusion Criteria: * Outpatients at the Department of Anesthesiology and Pain Medicine or the Department of Physical Medicine \& Rehabilitation of the study site who received a prescription for opioid analgesics (oral, transdermal, sublingual, or buccal formulations containing oxycodone, fentanyl, tapentadol, hydrocodone, or morphine) due to chronic non-cancer pain during the study evaluation period (from IRB approval date to September 30, 2025) * Adults aged ≥19 years and \<80 years * Patients who voluntarily signed a written informed consent form after receiving a full explanation of the study and understanding its purpose Exclusion Criteria: * Patients with active cancer * Patients diagnosed with sickle cell disease * Patients diagnosed with a life-limiting illness eligible for hospice or palliative care as defined in Article 2 of the 'ACT ON HOSPICE AND PALLIATIVE CARE AND DECISIONS ON LIFE-SUSTAINING TREATMENT FOR PATIENTS AT THE END OF LIFE' * Pregnant patients * Patients who were prescribed opioid analgesics within the past month for postoperative pain management * Patients who were prescribed opioid analgesics within the past month for newly developed pain * Patients with communication difficulties * Patients who were prescribed buprenorphine for the treatment of opioid use disorder * Patients who are deemed inappropriate for study participation at the discretion of the investigator
Contact & Investigator
So Hyun Lee, MS
PRINCIPAL INVESTIGATOR
Korea University Guro Hospital
Frequently Asked Questions
Who can join the NCT07102446 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 79 Years, studying Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07102446 currently recruiting?
Yes, NCT07102446 is actively recruiting participants. Contact the research team at pharm23@kumc.or.kr for enrollment information.
Where is the NCT07102446 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07102446 clinical trial?
NCT07102446 is sponsored by Korea University Guro Hospital. The principal investigator is So Hyun Lee, MS at Korea University Guro Hospital. The trial plans to enroll 70 participants.